Abstract:
Objective: The study was conducted to elicit the pathogenetic response of Hygrophila
spinosa in homoeopathic potencies on healthy human volunteers.
Methodology: The drug Hygrophila spinosa was proved by the Central Council for
Research in Homoeopathy (CCRH) through randomized, double-blind, placebocontrolled
method. The proving was conducted at three centres viz. Central Research
Institute (H), [CRI (H)] Noida, Drug Proving Unit [DPU], Bhubaneswar and Regional
Research Institute (H) [RRI (H)], Kolkata. The drug was proved in two potencies (6C and
30C) on 48 apparently healthy volunteers who were selected after conducting pre-trial
medical examinations by the medical specialists and routine laboratory investigations.
32 of them where kept on interventional drug trial and remaining took placebo. At CRI
(H), NOIDA, 56 dose schedule (i.e. 56 doses of drug/placebo were consumed in each
batch) was followed while at DPU, Bhubaneswar and at RRI (H), Kolkata, 12 dose
schedule (i.e. 12 doses of drug/placebo were to be consumed in each batch) was
followed. The symptoms generated during the trial period were noted by the volunteers
and elaborated by the Proving Masters which were compiled at Homoeopathic Drug
Proving-cum-Data Processing cell of CCRH headquarters after decoding.
Results: Out of 32 provers who were on interventional drug trial, only 14 manifested
symptoms. The drug was able to produce symptoms in both the potencies. 92 symptoms
appeared during the drug trial from various locations.
Conclusion: The drug pathogenesis evolved indicates its therapeutic use for urticaria,
frontal sinusitis, conjunctivitis, stomatitis, gastroenteritis, nausea (morning sickness),
intermittent fever etc.